Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease ...

Investing.com -- Despite record-high stock prices, investor sentiment has taken a decidedly bearish turn in recent weeks, a development that Yardeni Research views as a contrarian bullish signal.

Elevance Health's financial outlook for FY 2025 anticipates GAAP diluted earnings per share (EPS) to be in the range of $30.40 to $31.10 and adjusted diluted EPS to be in the range of $34.15 to $34.85 ...